The Game Awards 2022 are a wrap, and Elden Ring took home the biggest award of the night: Game of the Year. God of War Ragnarok also did pretty well for itself, taking home a handful of awards.

World Report 2022, Human Rights Watch’s 32nd annual review of human rights trends around the globe, reviews developments in more than 100 countries. In his introductory essay, Executive Director ...

2022 was a year both heartbreaking and hopeful, as the country felt the loosening of the grasp of COVID-19, while inflation ran rampant along with the tragic loss of too many innocent lives. This year ...

HIGHS Punchy acceleration, lithe handling, Long Range model boasts impressive driving range. LOWS Highway driving saps range, all-digital interior may irk some drivers, fit-and-finish could be better.

HIGHS Spry handling, eager powertrains, sporty exterior styling. LOWS Standard interior materials don't impress, snug rear seat, most rivals offer more cargo space. VERDICT Its refined chassis, strong ...

SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) on October 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma ...

Thanks to DNA evidence, charges have been filed in a case that's been under investigation for three years. Tre Goins faces a list of charges — including aggravated assault, recklessly endangering ...

HOME FROM THE FRONT YARD. GREENVILLE COUNTY DEPUTIES SAY A MAN WHO WAS RECENTLY ARRESTED IN CONNECTION WITH A COLD CASE IS FACING NEW CHARGES IN A SECOND INVESTIGATION ON OCTOBER 15TH, DEPUTIES ...

GREENVILLE COUNTY, S.C. (WSPA) – A Greenville County inmate who was recently charged in a murder from 2023 is now facing separate kidnapping and sexual assault charges from 2022. 49-year-old Robert ...

REDMOND, Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral ...

- Results from the BL-B01D1-303 (NCT06118333) phase III trial presented in a late-breaking oral presentation at ESMO represents the first data readout for iza-bren from a registration enabling study ...

Iza-bren showed a significantly higher ORR of 54.6% compared to 27.0% with chemotherapy in recurrent/metastatic NPC patients. The study demonstrated clinically meaningful improvements in PFS and ...